Acadia Pharmaceuticals' rare disease drug fails main goal in late-stage trial
24/09/2025 12:03
Sept 24 (Reuters) - Acadia Pharmaceuticals ACAD.O said on Wednesday that its experimental drug to treat a rare metabolic condition failed to meet the main goal in a late-stage study. (Reporting by Sneha S K; Editing by Sahal Muhammed) ((Sneha.SK@thomsonreuters.com;))
Recent news on Acadia Pharmaceuticals
See all newsUS RESEARCH ROUNDUP-Chevron, Exxon Mobil, GoDaddy
U.S. STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
US STOCKS ON THE MOVE-Charles River, Oracle, TD Synnex
Acadia's Alzheimer's psychosis drug misses main goal of mid-stage study (updated)
U.S. STOCKS ON THE MOVE-CoreWeave, Versant Media, BlackBerry